CKD OTTO Pharmaceuticals
- Company typePrivate
- Founded2015
- HeadquartersSelatan, Indonesia
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CKD OTTO Pharmaceuticals does
PT CKD OTTO Pharmaceuticals is an Indonesia-based, joint-venture oncology manufacturer established in September 2015 between South Korea's Chong Kun Dang Pharm (technology and product expertise) and Indonesia's OTTO Pharmaceutical Industries / MENSA Group (local market access). The company operates a USD 30 million, 12,588 m² GMP-certified facility in Cikarang, West Java, producing lyophilized powder and small-volume liquid injectable oncology drugs across a broad portfolio — including Gemcitabine, Paclitaxel, Oxaliplatin, Docetaxel, Doxorubicin, Epirubicin, Carboplatin, Methotrexate, Pemetrexed, Bortezomib, and the Bevacizumab biosimilar BEVABELL — at an annual capacity of 1.6 million vials. Its core manufacturing technology is a closed containment platform using isolator and CRABS (Closed Restricted Access Barrier System) with single-use bags and filters, transferred from the Korean parent to prevent cytotoxic contamination, and it holds both BPOM GMP (Sept 2018) and MUI Halal (Feb 2019) certifications, the latter making it the first halal-certified oncology manufacturer in Indonesia and positioning it for Muslim-majority export markets.
The company serves two primary customer segments: Indonesian hospitals and healthcare facilities procuring oncology injectables through direct field sales and the BPJS Kesehatan e-Catalogue, and international distributors/state-owned pharmaceutical partners (most notably Saidal Group in Algeria under a USD 32M, five-year supply agreement through 2026) covering MENA, GCC, ASEAN, and EU markets. Revenue is generated through one-time product sales of branded oncology injectables domestically and internationally, plus a newer contract services line spanning CMO (sterile injectables manufacturing), CRO (stability testing and process validation), and CSO (sales and marketing support). Pricing is set through institutional tenders and the government e-Catalogue system rather than retail channels, and the company targets 30% of the Indonesian anti-cancer drug market and 50% of its production volume allocated to global markets.
CKD OTTO Pharmaceuticals firmographics
Firmographics- Name
- CKD OTTO Pharmaceuticals
- Legal name
- PT CKD OTTO Pharmaceuticals
- Website
- https://ckd-otto.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
CKD OTTO Pharmaceuticals industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where CKD OTTO Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Selatan
- HQ country
- Indonesia
- HQ region
- Asia
Offices2 records
Markets served
CKD OTTO Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales (Domestic): Sale of oncology drugs (chemotherapy, biosimilar, immunosuppressant products) to Indonesian hospitals and healthcare facilities. Products include injectables such as Gemcitabine, Paclitaxel, Oxaliplatin, Docetaxel, Doxorubicin, Epirubicin, Carboplatin, Methotrexate, Pemetrexed, Bortezomib, Bevacizumab, and others.
- Export Sales: Export of anticancer drugs to international markets including Algeria (Saidal Group - $32 million deal over 5 years), MENA region, Europe, and ASEAN countries. Initial deal with Saidal Group valued at $18 million for 6 SKUs over 3 years.
- Contract Manufacturing Organization (CMO): Contract manufacturing of oncology products in sterile liquid injection and lyophilized powder dosage form for third-party partners.
- Contract Research Organization (CRO): Stability testing and process validation services provided to partners.
- Contract Sales Organization (CSO): Support for sales and marketing strategies in oncology and non-oncology fields for local and global market.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Hospital and healthcare institution procurement |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
CKD OTTO Pharmaceuticals product offering
Product offeringCore offering
PT CKD OTTO Pharmaceuticals manufactures and sells oncology pharmaceutical products including anti-cancer injectables in lyophilized powder and small volume liquid injection dosage forms for hospitals and healthcare facilities. The company also offers contract manufacturing (CMO), contract research (CRO), and contract sales organization (CSO) services for oncology and non-oncology products to global pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Products and services
- BEVABELL Brand of Bevacizumab, an oncology injectable used for cancer treatment, supplied to hospitals and healthcare facilities.
- IRINOBELL Brand of Irinotecan, an oncology injectable used for cancer treatment, supplied to hospitals and healthcare facilities.
- VINOBELL Brand of Vinorelbine, an oncology injectable used for cancer treatment, supplied to hospitals and healthcare facilities.
- TEZOBELL Brand of an oncology injectable used for cancer treatment, supplied to hospitals and healthcare facilities.
- PEMECINE Brand of Pemetrexed, an oncology injectable used for cancer treatment including lung cancer, supplied to hospitals and healthcare facilities.
- TANAXEL Brand of Paclitaxel, an oncology injectable used for breast, ovarian, and lung cancer treatment, supplied to hospitals and healthcare facilities.
- BELOTAXEL Brand of Docetaxel, an oncology injectable used for breast, lung, and prostate cancer treatment, supplied to hospitals and healthcare facilities.
- BELLOXA Brand of Oxaliplatin, an oncology injectable used for colorectal cancer treatment, supplied to hospitals and healthcare facilities.
- KEMODOXIN Brand of Doxorubicin, an oncology injectable used for various cancer treatments, supplied to hospitals and healthcare facilities.
- KEMPIRIN Brand of Epirubicin, an oncology injectable used for cancer treatment, supplied to hospitals and healthcare facilities.
- Contract Manufacturing Organization (CMO) Services Contract manufacturing of oncology products in sterile liquid injection and lyophilized powder dosage forms for third-party pharmaceutical partners globally.
- Contract Research Organization (CRO) Services Stability testing and process validation services for oncology and pharmaceutical products, provided to partners.
- Contract Sales Organization (CSO) Services Sales and marketing strategy support for oncology and non-oncology products in local and global markets, provided to partners.
Quantifiable outcome
- 30% target market share of Indonesian anti-cancer drug market
- +3 more outcomes
Companies that use CKD OTTO Pharmaceuticals
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
CKD OTTO Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CKD OTTO Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Saidal Group (Algeria)coreExport agreement worth USD 32 million signed between CKD OTTO and Saidal Group. CKD OTTO will ship anticancer injections produced at its Indonesian plant to Algeria for 5 years until 2026. Products supplied immediately to local hospitals through bidding. Algeria is the 2nd largest pharmaceutical market in MENA region with USD 4 billion market value.
- Saidal Group (Algeria)coreBusiness collaboration between CKD OTTO and Saidal Group (Algerian state-owned pharmaceutical company) for oncology products. Initial MOU signed December 2020. Business model: export of oncology products manufactured in Indonesia in bulk worth USD 18 million with 6 SKUs during the next 3 years. Phase 2 includes technology transfer once Saidal's oncology manufacturing plant is built. Signing ceremony attended by CEO of Saidal Group, President Director of CKD OTTO, and Head of Indonesia NADFC.
- Chong Kun Dang Pharm (Korea)coreJoint venture partner - leading South Korean pharmaceutical company (CKD Pharm) providing technology transfer, production systems, and oncology product expertise. CKD Pharma has been operating since 1972 with R&D focus on innovative product development for global markets.
- Otto Pharmaceutical Industries / MENSA Group (Indonesia)coreJoint venture partner - Indonesian pharmaceutical company and member of MENSA Group, providing local market access, regulatory navigation, and distribution network within Indonesia.
- Kyongbo (Korea)minorRaw material supplier subsidiary of Chong Kun Dang (CKD). CKD OTTO imports raw materials from Kyongbo for oncology drug manufacturing in Indonesia due to lack of domestic raw material production.
- Chong Kun Dang Kochon FoundationminorScholarship foundation under Chong Kun Dang providing annual scholarships to outstanding pharmacy students at University of Indonesia (UI) and Bandung Institute of Technology (ITB). Program in its 9th year in 2025, supporting 10 students from each university annually with full scholarships.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
CKD OTTO Pharmaceuticals competitors and assessment
Company assessmentRegional players
- PT Sanbe Farma: Indonesian pharmaceutical manufacturer with oncology products and sterile injectable capabilities, included in e-Catalogue procurement. Comparable because it competes with CKD OTTO domestically on Indonesian hospital tenders and shares the local fill-finish/oncology injection focus.
- PT Dexa Medica: Indonesia-based pharma group with oncology and sterile injectable products, exporting to ASEAN and MENA. Comparable as a domestic Indonesian competitor pursuing the same import-substitution strategy in oncology injectables.
- Saudi Arabian SAJA Pharmaceuticals: Saudi-based sterile injectable manufacturer aligned with SFDA approval pathway; CKD OTTO has explicitly stated SFDA readiness. Comparable because it is a regional MENA oncology injectable supplier CKD OTTO will need to outcompete or partner with to win Saudi/GCC tenders.
- Kalbe Farma: Indonesia's largest pharmaceutical company with an oncology franchise (Kalbe Genuks) and broad distribution into Indonesian hospitals. Comparable because it is the principal domestic competitor CKD OTTO must displace to reach its 30% anti-cancer market share target.
Direct peers
- Hetero Drugs: Large Indian oncology generics manufacturer active in MENA and ASEAN with broad chemotherapy injectable portfolio. Comparable because it pursues the same low-cost injectable oncology export playbook targeting Muslim-majority and emerging markets.
- Chong Kun Dang Pharm: Parent company and Korean JV partner; produces oncology injectables including biosimilars with established oncology expertise since 1972. Directly comparable because it is the upstream source of CKD OTTO's technology and product portfolio.
Broad incumbents
- Fresenius Kabi: Global leader in injectable oncology generics with extensive CMO/CDMO operations. Comparable because it competes with CKD OTTO in lyophilized oncology injectables and is a benchmark scale and quality reference in the segment.
- Dr. Reddy's Laboratories: Indian multinational with one of the largest generic injectable oncology portfolios, exporting to MENA, ASEAN, and emerging markets. Comparable because it competes head-to-head with CKD OTTO on cost-competitive chemotherapy generics in the same target geographies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
CKD OTTO Pharmaceuticals social profiles
Digital presenceCKD OTTO Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
CKD OTTO Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles8 records
CKD OTTO Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CKD OTTO Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CKD OTTO Pharmaceuticals
What does CKD OTTO Pharmaceuticals do?
PT CKD OTTO Pharmaceuticals manufactures and sells oncology pharmaceutical products including anti-cancer injectables in lyophilized powder and small volume liquid injection dosage forms for hospitals and healthcare facilities. The company also offers contract manufacturing (CMO), contract research (CRO), and contract sales organization (CSO) services for oncology and non-oncology products to global pharmaceutical partners.
Is CKD OTTO Pharmaceuticals a public or private company?
CKD OTTO Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was CKD OTTO Pharmaceuticals founded?
CKD OTTO Pharmaceuticals was founded in 2015. It employs 51 to 100 people.
Where is CKD OTTO Pharmaceuticals based?
CKD OTTO Pharmaceuticals is headquartered in Selatan, Indonesia, in the Asia region.
How does CKD OTTO Pharmaceuticals make money?
Five revenue lines are on record. Pharmaceutical Product Sales (Domestic) is the primary driver. The others are export Sales, contract Manufacturing Organization (CMO), contract Research Organization (CRO) and contract Sales Organization (CSO).
Who are CKD OTTO Pharmaceuticals's main competitors?
Regional players on record are PT Sanbe Farma, PT Dexa Medica, Saudi Arabian SAJA Pharmaceuticals and Kalbe Farma. Direct peers are Hetero Drugs and Chong Kun Dang Pharm. Broad incumbents are Fresenius Kabi and Dr. Reddy's Laboratories.
Does CKD OTTO Pharmaceuticals have an API?
No public API is recorded for CKD OTTO Pharmaceuticals.
What industry is CKD OTTO Pharmaceuticals in?
CKD OTTO Pharmaceuticals's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.